Talphera (NASDAQ:TLPH) Posts Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Talphera (NASDAQ:TLPH) issued its earnings results on Monday. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.02, FiscalAI reports.

Here are the key takeaways from Talphera’s conference call:

• 50% enrollment in the NEPHRO CRRT registrational study triggered a financing tranche (gross proceeds of $4.1M); management reports $20.4M cash & investments and says remaining tranches should provide runway through a potential FDA approval with enrollment completion and PMA submission expected in the second half of 2026.
• Key opinion leaders emphasized a clear unmet need for CRRT anticoagulation — current options (heparin and citrate) are either unpredictable/systemic or effective but operationally complex, and many centers use no anticoagulation because of these limitations.
• Investigators said nafamostat (Niyad) is viewed as simpler to use, largely regional (stays in the circuit), easier to titrate, and likely to be adopted as a frontline option at many sites — potentially extending filter life, reducing nursing burden, and increasing anticoagulation uptake.
• The trial’s conservative inclusion/exclusion criteria (e.g., baseline ACT and bleeding-risk restrictions) have made enrollment challenging and contributed to a modest timeline slip, creating execution risk even though management says enrollment pace has improved.

Talphera Price Performance

Talphera stock opened at $0.80 on Tuesday. The firm has a market capitalization of $37.34 million, a P/E ratio of -2.11 and a beta of 0.47. The stock has a fifty day moving average price of $0.89 and a two-hundred day moving average price of $1.05. Talphera has a 52-week low of $0.38 and a 52-week high of $1.57.

Insider Activity

In other news, CEO Vincent J. Angotti bought 105,364 shares of the company’s stock in a transaction that occurred on Thursday, February 12th. The stock was acquired at an average price of $0.81 per share, for a total transaction of $85,344.84. Following the transaction, the chief executive officer directly owned 586,954 shares of the company’s stock, valued at $475,432.74. This trade represents a 21.88% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CFO Raffi Asadorian purchased 45,000 shares of the business’s stock in a transaction that occurred on Thursday, February 12th. The shares were purchased at an average cost of $0.81 per share, with a total value of $36,450.00. Following the completion of the acquisition, the chief financial officer directly owned 91,256 shares in the company, valued at $73,917.36. The trade was a 97.28% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased a total of 220,364 shares of company stock worth $178,495 over the last 90 days. 5.70% of the stock is currently owned by company insiders.

Institutional Trading of Talphera

Several large investors have recently added to or reduced their stakes in the company. Nantahala Capital Management LLC increased its holdings in shares of Talphera by 75.3% during the third quarter. Nantahala Capital Management LLC now owns 3,492,519 shares of the company’s stock worth $3,120,000 after buying an additional 1,500,000 shares in the last quarter. Cantor Fitzgerald L. P. bought a new stake in Talphera during the 4th quarter worth approximately $658,000. Geode Capital Management LLC grew its position in Talphera by 107.0% during the 4th quarter. Geode Capital Management LLC now owns 342,987 shares of the company’s stock worth $391,000 after acquiring an additional 177,294 shares during the last quarter. Renaissance Technologies LLC increased its holdings in Talphera by 412.6% during the 4th quarter. Renaissance Technologies LLC now owns 257,380 shares of the company’s stock valued at $293,000 after purchasing an additional 207,166 shares in the last quarter. Finally, Diadema Partners LP acquired a new stake in Talphera during the 4th quarter valued at $156,000. 37.67% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Talphera in a research note on Wednesday, January 21st. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Talphera has an average rating of “Hold” and an average target price of $6.00.

About Talphera

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe.